Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.61 |
| ▸ | KIF11 | P52732 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 5/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL28624662 | 1.00 | GSR (0.61) | GSRKIF11FOLH1POLBKMT2A | |
| Lysine SCHEMBL3907029 | 0.91 | GSR (0.65) | GSRKIF11POLBKMT2ATDP1 | |
| Lysine SCHEMBL28960644 | 0.91 | GSR (0.65) | GSRKIF11POLBKMT2ATDP1 | |
| Lysine SCHEMBL28623413 | 0.91 | GSR (0.65) | GSRKIF11POLBKMT2ATDP1 | |
| Lysine SCHEMBL28623414 | 0.91 | GSR (0.65) | GSRKIF11POLBKMT2ATDP1 | |
| Lysine SCHEMBL28616706 | 0.89 | GSR (0.62) | GSRKIF11POLBKMT2ATDP1 | |
| Lysine SCHEMBL28922054 | 0.89 | GSR (0.62) | GSRKIF11POLBKMT2ATDP1 | |
| Lysine SCHEMBL28922053 | 0.89 | GSR (0.62) | GSRKIF11POLBKMT2ATDP1 | |
| Lysine SCHEMBL28616703 | 0.89 | GSR (0.62) | GSRKIF11POLBKMT2ATDP1 | |
| Isophthalic Acid SCHEMBL14343321 | 0.89 | GSR (0.62) | GSRFOLH1POLBKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113354809-B | Amino-terminated ionic liquid grafted polylysine isophthalamide, synthetic method and application in low-temperature cell preservation | 天津大学 | 2022-09-09 | — | — | CN | claimed |
| CN-113354809-A | Amino-terminated ionic liquid grafted polylysine isophthalamide, synthetic method and application in cell cryopreservation | 天津大学 | 2021-09-07 | — | — | CN | claimed |
| WO-2011089391-A1 | MAMMALIAN CELL PRESERVATION METHODS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-07-28 | — | — | WO | claimed |
| US-20260034202-A1 | PAYLOAD DELIVERY SYSTEM | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| US-20250381286-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12364769-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12351637-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250170260-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250171544-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250152726-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2025-05-15 | — | — | US | disclosed |
| US-12234290-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-111655268-A | Nucleic acid-polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2020-09-11 | — | — | CN | disclosed |
| WO-2011089391-A1 | MAMMALIAN CELL PRESERVATION METHODS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011089391-A1 | MAMMALIAN CELL PRESERVATION METHODS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-07-28 | — | — | WO | disclosed |
| WO-2009128789-A1 | VESICLES FOR INTRACELLULAR DRUG DELIVERY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-10-22 | — | — | WO | disclosed |
| US-20060172418-A1 | Hypercoiling polymers and their use in cellular delivery | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES (GB) | 2006-08-03 | — | — | US | disclosed |
| EP-1567194-A1 | HYPERCOILING POLYMERS AND THEIR USE IN CELLULAR DELIVERY | Cambridge University Technical Services Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| EP-1499358-A1 | PH-SENSITIVE POLYMER | Röhm GmbH & Co. KG (DE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2004052402-A1 | HYPERCOILING POLYMERS AND THEIR USE IN CELLULAR DELIVERY | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003092732-A1 | PH-SENSITIVE POLYMER | Röhm GmbH & Co. KG (DE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381286-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | NSUN2, UPF1, SNRPE | GSR 3474/4885KIF11 3545/4885FOLH1 1948/4885 |
| US-12234290-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | GSR 4580/4885KIF11 1533/4885FOLH1 266/4885 |
| US-20250170260-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | NSUN2, UPF1, SNRPE | GSR 3474/4885KIF11 3545/4885FOLH1 1948/4885 |
| US-20250152726-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | GSR 4557/4885KIF11 1569/4885FOLH1 281/4885 |
| US-12351637-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | GSR 4580/4885KIF11 1533/4885FOLH1 266/4885 |
| US-20260034202-A1 | PAYLOAD DELIVERY SYSTEM | TLR9, TLR2, TLR3 | GSR 3756/4885KIF11 935/4885FOLH1 3210/4885 |
| US-12364769-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | GSR 4557/4885KIF11 1569/4885FOLH1 281/4885 |
| US-20250171544-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | GSR 4580/4885KIF11 1533/4885FOLH1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.